LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

It’s here: Dexcom is kicking off the international rollout of the newest generation of its real-time continuous glucose monitor, the G7, to help adults and children with diabetes digitally track their ...

DexCom is building increasingly user-friendly devices that continuously monitor blood glucose levels, and a new collaboration between DexCom and Google could lead to the smallest such devices yet.

Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

DexCom, Inc. DXCM announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has ...

Dexcom is hoping to win FDA approval to begin selling its G7 continuous glucose monitor in the U.S. later this year. (Shown here with an Apple Watch). · MedTech Dive · Courtesy of Dexcom A warning ...

Improving care There are 387 million diabetic people worldwide and that number is estimated to grow to nearly 600 million by 2035. Because diabetes can lead to life-threatening conditions, such as ...